Fatiha Chermat

1.1k citations
20 papers · 78 · h-index 6

Impact in

  • Hematology
    • Acute Myeloid Leukemia Research
    • Hematopoietic Stem Cell Transplantation
    • Chronic Myeloid Leukemia Treatments
  • Genetics
    • Myeloproliferative Neoplasms: Diagnosis and Treatment
    • Hemoglobinopathies and Related Disorders

Papers in

  • Hematology 17
    • Acute Myeloid Leukemia Research 16
    • Chronic Myeloid Leukemia Treatments 4
  • Genetics 8
    • Hemoglobinopathies and Related Disorders 4
    • Chronic Lymphocytic Leukemia Research 2
Co-authors
Pierre Fenaux (16 shared papers)Sylvain Thépot (8 shared papers)Lionel Adès (8 shared papers)Thomas Cluzeau (8 shared papers)Niels Vejlstrup (3 shared papers)Odile Beyne‐Rauzy (2 shared papers)Nina Toft (2 shared papers)Eduard J. van Beers (3 shared papers)
Journals
Blood (15 papers)Leukemia Research (2 papers)BMJ Open (1 paper)Transfusion (1 paper)Blood Advances (1 paper)
Partner nations
FranceNetherlandsCanada

In The Last Decade

Fatiha Chermat

16 papers receiving 78 citations

Peers

Fatiha Chermat
Comparison fields: 5 of 25
  • Hematology 54
  • Genetics 15
  • Oncology 12
  • Immunology 8
  • Emergency Medicine 3
Replace Anne‐Sophie Alary with:
Anne‐Sophie Alary France
Kristin L Koenig United States
Habib El‐Khoury United States
Florence Rabian France
Cláudia Moreira Portugal
Lindsay Rein United States
Tigran Torosian Poland
Sumeet Mirgh India
Şeniz Öngören Aydın Türkiye
Vladimir Ivanov Russia
Fatiha Chermat relative to Anne‐Sophie Alary France Anne‐Sophie Alary's profile →
Citations per field
00.5×1.6×
Anne‐Sophie Alary · 1×
Citations per year

Countries citing papers authored by Fatiha Chermat

Since Specialization
Citations

This map shows the geographic impact of Fatiha Chermat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatiha Chermat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatiha Chermat more than expected).

Fields of papers citing papers by Fatiha Chermat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fatiha Chermat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatiha Chermat. The network helps show where Fatiha Chermat may publish in the future.

Co-authors

The 25 scholars most cited alongside Fatiha Chermat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Fatiha Chermat Line = papers co-authored together Fatiha Chermat links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1
Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial
Blood ·Anne Sophie Kubasch, Freya Schulze, Katharina S. Götze, Jan Krönke, Katja Sockel, Jan Moritz Middeke, Fatiha Chermat, Silke Gloaguen, Martin Puttrich, Carmen Weigt, Katja Jersemann, Pierre Fenaux, Richard F. Schlenk, Aristoteles Giagounidis, Lionel Adès, Anna Mies, Uta Oelschlaegel, Uwe Platzbecker
201814
2
CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM
Blood ·Pierre Péterlin, Pascal Turlure, Patrice Chevallier, Marie-Pierre Gourin, Pierre‐Yves Dumas, Sylvain Thépot, Anna Berceanu, Sophie Park, Thomas Cluzeau, José Miguel Torregrosa Diaz, Louis Devron, Sylvie Chevret, Marie C. Béné, Yannick Le Bris, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli‐Salazar, Pierre Fenaux
202114
3
A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure
Leukemia Research ·Sylvain Thépot, Simone Boehrer, Valérie Seegers, Thomas Prébet, Odile Beyne‐Rauzy, Eric Wattel, Jacques Delaunay, Emmanuel Raffoux, Mathilde Hunault, Éric Jourdan, Fatiha Chermat, Marie Sébert, Guido Kroemer, Pierre Fenaux, Lionel Adès
201413
4
Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study
Blood ·Lionel Adès, Thomas Cluzeau, Thibault Comont, Loréa Aguinaga, Aspasia Stamatoullas, Mathieu Meunier, Emmanuel Gyan, Alice Garnier, Maud D’Aveni, Sylvain Thépot, Marie Sébert, Marius Moldovan, Anouk Walter‐Petrich, Karine Lemarie, Fatiha Chermat, Michaëla Fontenay, Sylvie Chevret, Pierre Fenaux
20247
5
Designing a single-arm phase 2 clinical trial of mitapivat for adult patients with erythrocyte membranopathies (SATISFY): a framework for interventional trials in rare anaemias – pilot study protocol
BMJ Open ·Andreas Glenthøj, Eduard J. van Beers, Richard van Wijk, Minke A.E. Rab, Evelyn Groot, Niels Vejlstrup, Nina Toft, Selma Kofoed Bendtsen, Jesper Petersen, Jens Helby, Fatiha Chermat, Pierre Fenaux, Kevin H.M. Kuo
20246
6
Red blood cell transfusion burden in myelodysplastic syndromes (MDS) with ring Sideroblasts (RS): A retrospective multicenter study by the Groupe Francophone des Myélodysplasies (GFM)
Transfusion ·Claire Jouzier, Amina Cherait, Pascale Cony‐Makhoul, Jean‐François Hamel, Mélanie Véloso, Sylvain Thépot, Thomas Cluzeau, Aspasia Stamatoullas, Alice Garnier, Agnès Guerci‐Bresler, Sophie Dimicoli‐Salazar, Gian Matteo Pica, Stéphane Chèze, Clémence Santana, Fatiha Chermat, Pierre Fenaux, Sophie Park
20226
7
Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists
Blood Advances ·Igor Stojkov, Annette Conrads‐Frank, Ursula Rochau, Karin A. Koinig, Marjan Arvandi, Sibylle Puntscher, Corine van Marrewijk, Pierre Fenaux, Argiris Symeonidis, Fatiha Chermat, Hege Garelius, David Bowen, Moshe Mittelman, Elvira Mora, Théo de Witte, Fabio Efficace, Uwe Siebert, Reinhard Stauder
20214
8
Eltrombopag in Chronic Myelomonocytic Leukemia (CMML) with Severe Thrombocytopenia: Final Results of a Multicenter Phase II Study
Blood ·Florence Rabian, Jérôme Lambert, Daniela Barbieri, Bérengère Gruson, Sylvain Thépot, Thorsten Braun, Norbert Vey, Jacques Delaunay, Laurence Legros, Julie Lejeune, Anouk Walter‐Petrich, Rosa Sapena, Nathalie Droin, Fatiha Chermat, Françoise Porteu, Daniel Lusina, Lionel Adès, Éric Solary, Pierre Fenaux, Raphaël Itzykson
20202
9
Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure
Blood ·Thomas Prébet, Thorsten Braun, Odile Beyne‐Rauzy, Eric Wattel, François Dreyfus, A. Stamatoulas, Shanti Amé, Jacques Delaunay, Emmanuel Raffoux, Fatiha Chermat, Pierre Fenaux, Norbert Vey
20122
10
Azacitidine (AZA) Combined with Idarubicin in Higher Risk MDS - Results of a Phase I/II Study By the Groupe Francophone Des Myelodysplasies (GFM)
Blood ·Marie Sébert, Aspasia Stamatoullas, Thorsten Braun, Jacques Delaunay, Benoît De Renzis, Ramzi Jeddi, Balkis Meddeb, Mathilde Hunault Berger, Benedicte Samey, Fatiha Chermat, Sylvie Chevret, Cendrine Chaffaut, Pierre Fenaux, Lionel Adès
20152
11
Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM)
Blood ·Claire Jouzier, Amina Cherait, Pascale Cony‐Makhoul, Sylvain Thépot, Thomas Cluzeau, Aspasia Stamatoulas Bastard, Pierre Péterlin, Agnes Guerci Bresler, Sophie Dimicoli‐Salazar, Gian-Matteo Pica, Stéphane Chèze, Clémence Santana, Fatiha Chermat, Pierre Fenaux, Sophie Park
20202
12
A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study
Blood ·Thomas Prébet, Thorsten Braun, Odile Beyne Rauzy, François Dreyfus, Aspasia Stamatoullas, Eric Wattel, Shanti Amé, Emmanuel Raffoux, Jacques Delaunay, Célia Salanoubat, Isabelle Mathieu, Fatiha Chermat, Lionel Adès, Pierre Fenaux, Norbert Vey
20102
13
Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II - Results from the 8-Week Dose-Escalation Period
Blood ·Thomas Doeven, Eduard J. van Beers, Richard van Wijk, Evelyn Groot, Joline L. Saes, Jennifer Bos, Jonathan R.A. de Wilde, Minke A.E. Rab, Selma Kofoed Bendtsen, Jesper Petersen, Niels Vejlstrup, Jens Helby, Adeline Gladieux, Fatiha Chermat, Pierre Fenaux, Kevin H.M. Kuo, Andreas Glenthøj
20241
14
Phase I/II Clinical Trial Evaluating Azacitidine + Venetoclax + Donor Lymphocyte Infusion in Post-Transplant Relapse Myelodysplastic Syndromes and Acute Myeloid Leukemia: Preliminary Results of Ventograft, a GFM Study
Blood ·Thomas Cluzeau, Marie Sébert, Michaël Loschi, Lionel Adès, Sylvain Thépot, Martin Carré, Nicolas Duployez, Rosa Sapena, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, Marie Robin
20231
15
Safety and Efficacy of Mitapivat in Adult Patients with Erythrocyte Membranopathies (SATISFY)
Blood ·Andreas Glenthoej, Eduard J. van Beers, Richard van Wijk, Minke A.E. Rab, Evelyn Groot, Niels Vejlstrup, Selma Kofoed Bendtsen, Nina Toft, Jesper Petersen, Jens Helby, Fatiha Chermat, Pierre Fenaux, Kevin H.M. Kuo
20231
16
Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
Blood ·Yannick Le Bris, Simon Bouzy, Audrey Ménard, Pascal Turlure, Patrice Chevallier, Marie-Pierre Gourin, Pierre‐Yves Dumas, Sylvain Thépot, Anna Berceanu, Sophie Park, Thomas Cluzeau, José Miguel Torregrosa Diaz, Louis Devron, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli Salazar, Marie C. Béné, Pierre Fenaux, Pierre Péterlin
20221
17
A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-Based Therapy - Interim Analysis Results of the Impress Study
Blood ·Uwe Platzbecker, Steven Lane, Alice Garnier, Thomas Cluzeau, Odile Beyne Rauzy, Katharina S. Götze, Aristoteles Giagounidis, Deepak Singhal, A Kopecký, Fatiha Chermat, Lionel Adès
20240
18
Azacitidine (AZA) Combined with Idarubicin in Untreated Patients with High Risk MDS – Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies
Blood ·Lionel Adès, Benoît De Renzis, Ramzi Jeddi, Jacques Delaunay, Thorsten Braun, Mathilde Hunault Berger, Aspasia Stamatoullas, Laurence Sanhès, Benedicte Samey, Fatiha Chermat, B Meddeb, Pierre Fenaux
20120
19
A phase II study evaluating the efficacy and safety of imetelstat in patients with advanced myelodysplastic neoplasms or AML failing HMA-based therapy – interim analysis results of the IMpress study
Blood ·Lionel Adès, Steven Lane, Alice Garnier, Thomas Cluzeau, Odile Beyne Rauzy, Katharina S. Götze, Aristoteles Giagounidis, Deepak Singhal, Dominic Brauer, Carolyn Grove, Katharina Mohr, Fatiha Chermat, Joanna Nkyekyer, Uwe Platzbecker
20250
20
P149 Treatment of high risk MDS and AML post-MDS with azacytidine (AZA): current results of the French ATU program
Leukemia Research ·Claire Fabre, Marie Sébert, Enrique Hernández, Fatiha Chermat, Dominique Bordessoule, M.P. Chaury, C. Dartigeas, Stéphane de Botton, F. Dreyfus, Laurence Legros, Lionel Mannone, Anne Marfaing‐Koka, Maclaren Noel, Sophie Park, Thomas Prébet, Aspasia Stamatoullas, Norbert Vey, Pierre Fenaux
20070

About Fatiha Chermat

Fatiha Chermat is a scholar working on Hematology, Genetics, Molecular Biology, Epidemiology and Physiology, having authored 20 papers that have together received 78 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (16 papers), Histone Deacetylase Inhibitors Research (5 papers), Chronic Myeloid Leukemia Treatments (4 papers), Hemoglobinopathies and Related Disorders (4 papers), Erythrocyte Function and Pathophysiology (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and HIV/AIDS drug development and treatment (2 papers). The work is most often cited by research in Hematology (54 citations), Genetics (15 citations), Oncology (12 citations), Immunology (8 citations) and Emergency Medicine (3 citations). Fatiha Chermat has collaborated with scholars based in France, Netherlands and Canada. Frequent co-authors include Pierre Fenaux, Sylvain Thépot, Lionel Adès, Thomas Cluzeau, Niels Vejlstrup, Odile Beyne‐Rauzy, Nina Toft, Eduard J. van Beers, Alice Garnier and Éric Jourdan. Their work appears in journals such as Blood, Leukemia Research, BMJ Open, Transfusion and Blood Advances.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anne‐Sophie AlaryBreakdown of academic impact, for papers by Kristin L KoenigBreakdown of academic impact, for papers by Habib El‐KhouryBreakdown of academic impact, for papers by Florence RabianBreakdown of academic impact, for papers by Cláudia MoreiraBreakdown of academic impact, for papers by Lindsay ReinBreakdown of academic impact, for papers by Tigran TorosianBreakdown of academic impact, for papers by Sumeet MirghBreakdown of academic impact, for papers by Şeniz Öngören AydınBreakdown of academic impact, for papers by Vladimir Ivanov